We analyzed FcγRIIIA-158V/F and FcγRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcγRIIIA-158VV/VF and FcγRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome. ©2007 Ferrata Storti Foundation.
FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Palumbo, Giuseppe A.;Tibullo, Daniele;
2007-01-01
Abstract
We analyzed FcγRIIIA-158V/F and FcγRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcγRIIIA-158VV/VF and FcγRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome. ©2007 Ferrata Storti Foundation.| File | Dimensione | Formato | |
|---|---|---|---|
|
FcγRIIIA and FcγRIIA polymorphisms.pdf
solo gestori archivio
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
177.89 kB
Formato
Adobe PDF
|
177.89 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
